Brainstorm Cell Therapeutics Inc.
BCLI
$0.61
$0.000.51%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.99% | -18.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.44% | -16.70% | |||
| Operating Income | 20.44% | 16.70% | |||
| Income Before Tax | 27.45% | -1.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.45% | -1.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.45% | -1.36% | |||
| EBIT | 20.44% | 16.70% | |||
| EBITDA | 20.74% | 16.96% | |||
| EPS Basic | 43.20% | 25.42% | |||
| Normalized Basic EPS | 43.18% | 25.41% | |||
| EPS Diluted | 43.20% | 25.42% | |||
| Normalized Diluted EPS | 43.18% | 25.41% | |||
| Average Basic Shares Outstanding | 27.70% | 35.93% | |||
| Average Diluted Shares Outstanding | 27.70% | 35.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||